ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study.Journal of primary care & community healthObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including liraglutide and semaglutide, has expanded rapidly due to their effectiveness in weight management and glycemic control. Rising public interest, off-label cosmetic use, and prescription-free requests highlight the critical role of community pharmacists in ensuring appropriate patient counselling, safe dispensing, and rational use of these agents. This study aimed to assess the knowledge, attitudes, and practices of community pharmacists regarding GLP-1 RAs in Türkiye. Patients and Methods: A cross-sectional survey was conducted among 500 community pharmacists in Türkiye between January and April 2025. Data were collected using a structured, literature-based questionnaire covering sociodemographic characteristics, attitudes, knowledge, and professional practices. Knowledge was evaluated using a 25-item scoring system. Statistical analyses included descriptive statistics, chi-square tests, independent samples t-tests, and one-way ANOVA, with significance set at p<0.05. Results: Requests for semaglutide and liraglutide were primarily for weight loss purposes (82.6% and 79.4%, respectively), and these agents were often sought without a prescription (over 60%) or medical recommendation (over 35%). The mean knowledge score was 15.8±4.3. Differences were observed across gender, professional experience, and pharmacy setting (p<0.05), with higher scores among female pharmacists, those with more than 16 years of experience, and those working in shopping mall pharmacies. Although most respondents correctly identified both medications as GLP-1 RAs (85.6% for semaglutide; 83.6% for liraglutide), gaps remained in regulatory awareness and consistency of routine counselling. A substantial proportion perceived misuse, with over 60% reporting concerns for both medications. Conclusion: Community pharmacists demonstrate moderate knowledge and active involvement in counselling for GLP-1 RAs; however, gaps persist in addressing off-label demand and safety-related patient guidance. Targeted pharmacist education and clearer regulatory communication may enhance safe and evidence-based use of GLP-1 RAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.